Trial Profile
A Randomized, Open-label, Parallel Controlled, Multi-center Phase III Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Bevacizumab; Capecitabine; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Registrational; Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 30 Nov 2023 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 30 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 13 Sep 2022 Trial design presented at the 47th European Society for Medical Oncology Congress